Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Overview
Authors
Affiliations
Significance: Our study provides direct evidence for recurrent genetic aberrations preceding FL diagnosis, revealing the combination of BCL2 translocation with CREBBP KAT domain mutations as characteristic committed lesions of FL CPCs. Such prediagnostic mutations are detectable years before clinical diagnosis and may help discriminate individuals at risk for lymphoma development. This article is highlighted in the In This Issue feature, p. 1275.
Circulating tumor DNA in lymphoma: technologies and applications.
Fu L, Zhou X, Zhang X, Li X, Zhang F, Gu H J Hematol Oncol. 2025; 18(1):29.
PMID: 40069858 PMC: 11900646. DOI: 10.1186/s13045-025-01673-7.
Liquid biopsy in detecting early non-small cell lung cancer.
Rosell R, Santarpia M, Pedraz-Valdunciel C, Ciappina G, Aguilar A, Gimenez-Capitan A J Liq Biopsy. 2025; 1:100001.
PMID: 40027282 PMC: 11863710. DOI: 10.1016/j.jlb.2023.100001.
Primary thyroid B-cell lymphoma: molecular insights into its clonal evolution and relapse.
Tzioni M, Watanabe N, Chen Z, Wu F, Madej E, Makker J J Pathol. 2024; 265(2):123-131.
PMID: 39722652 PMC: 11717488. DOI: 10.1002/path.6380.
The POD24 challenge: where do we go from here for early progressors?.
Mondello P, Casulo C Hematology Am Soc Hematol Educ Program. 2024; 2024(1):301-309.
PMID: 39643981 PMC: 11665737. DOI: 10.1182/hematology.2024000662.
Witzig T, Taylor W, Mahoney D, Bamlet W, Foote P, Burger K Am J Hematol. 2024; 100(2):218-228.
PMID: 39564730 PMC: 11705204. DOI: 10.1002/ajh.27533.